New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
July 14, 2020 - Janssen announced the FDA approval of Tremfya (guselkumab), for the treatment of adult patients with active psoriatic arthritis (PsA).
Download PDF
Return to publications
